XBP1 and acute myeloid leukemia: Inhibition of XBP1 or ATF4 via shRNA leads to apoptosis in AML cells and significantly prolongs disease latency in vivo, linking reduced survival from JUN inhibition to decreased pro-survival UPR signaling [11].